Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5466]

ASCO 2014: New combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer

ASCO 2014: New combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent...

New approach for tackling drug resistance in AML

New approach for tackling drug resistance in AML

Mapping the human proteome

Mapping the human proteome

Researchers discover new way to combat drug resistance in skin cancer

Researchers discover new way to combat drug resistance in skin cancer

Potential new therapeutic approach identified for two types of pancreatic cancer

Potential new therapeutic approach identified for two types of pancreatic cancer

Blocking one protein may lead to new treatments for two types of pancreatic cancer

Blocking one protein may lead to new treatments for two types of pancreatic cancer

PV-10 data for break through therapy designation application highlighted by ASCO

PV-10 data for break through therapy designation application highlighted by ASCO

Radioimmunotherapy and gemcitabine combination shows early promise for metastatic pancreatic ductal cancer

Radioimmunotherapy and gemcitabine combination shows early promise for metastatic pancreatic ductal cancer

Scientists discover 'brakes' to stop cancer-causing 'car-crashes' in cells

Scientists discover 'brakes' to stop cancer-causing 'car-crashes' in cells

Research in several cancers reveals promising treatment strategies, new insights on screening, and obesity-cancer link

Research in several cancers reveals promising treatment strategies, new insights on screening, and obesity-cancer...

More from ecancer